Published On: Tue, Apr 28th, 2015

Tamir Capital soars after court ruling against Teva

Tamir Capital is invested in Proneuron, which successfully sued Teva for abuse of a license for its product.


Shares in Tamir Capital are soaring on lively volumes, following a Tel Aviv District Court ruling that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) infringed the terms of a license from Proneuron Biotechnologies, and that the intellectual property rights should be restored to Proneuron immediately. Teva was also ordered to pay costs of about $100, 000.

The judge found that “Teva made a mistaken professional decision and embarked on an efficacy trial that was not well planned, since it ought to have given greater weight to the pre-clinical findings and to have examined their significance further before starting a clinical trial.”… [READ MORE]


GLOBES logo-eng (1)Published by Globes [online], Israel business news –


Read more about: , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems